Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi
Executive Summary
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
You may also be interested in...
'Still The Place To Do Drug Innovation': China Biotech CEO Podcast With InnoCare’s Jasmine Cui
From founding to the approval and commercial launch of its first innovative drug took Beijing-based biotech InnoCare just seven years. After a listing in Hong Kong, the firm is now heading to Shanghai after obtaining the green light for a second listing from the STAR board.
Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.
China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey
After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.